Interaction between C-reactive protein and endothelin-1 in coronary artery disease

Cardiology

Volumn 107, Issue 4, 2007, Pages 340-344

  Gemici, Gökmen ^a,b   Erdim, Refik ^a   Tokay, Sena ^a   Tezcan, Hakan ^a   Fak, A Serdar ^a   Oktay, Ahmet ^a  

^a MARMARA UNIVERSITY   (Turkey)

^b NONE   (Turkey)

Author keywords

Atherosclerosis; C reactive protein; Coronary artery disease; Endothelin 1; Statin

Indexed keywords

C REACTIVE PROTEIN; ENDOTHELIN 1; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADVERSE OUTCOME; ARTICLE; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; HYPOTHESIS; MOLECULAR INTERACTION; PATHOPHYSIOLOGY; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN PROTEIN INTERACTION; SENSITIVITY ANALYSIS;

BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CORONARY ARTERIOSCLEROSIS; CROSS-SECTIONAL STUDIES; ENDOTHELIN-1; FEMALE; HUMANS; MALE; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES;

EID: 34249014984     PISSN: 00086312     EISSN: None     Source Type: Journal    
DOI: 10.1159/000099048     Document Type: Article

References (25)

1. Ross R: Atherosclerosis - an inflammatory disease. N Engl J Med 1999;340:115-126.
2. Haverkate F, Thompson SG, Pyke SD, Gallimore JR, Pepys MB: Production of C-reactive protein and risk of coronary events in stable and unstable angina. European concerted action on thrombosis and disabilities angina pectoris study group. Lancet 1997;349:462-466.
3. Liuzzo G, Biasucci LM, Gallimore JR: The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med 1994;331:417-424.
4. Rettersol L, Eikvar L, Bohn M, Bakken A, Erikssen J, Berg K: C-reactive protein predicts death in patients with previous premature myocardial infarction - a 10 year follow up study. Atherosclerosis 2002;160:433-440.
5. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH: Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336;973-979.
6. Lagrand WK, Visser CA, Hermens WT, Niessen HW, Verheugt FW, Wolbink GJ, Hack CE: C-reactive protein as a cardiovascular risk factor more than an epiphenomenon? Circulation 1999;100:96-102.
7. Munford RS: Statins and the acute-phase response. N Engl J Med 2001;344:2016-2018.
8. Lerman A, Edwards BS, Hallett JW, Heublein DM, Sandberg SM, Burnett JC Jr: Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N Engl J Med 1991;325:997-1001.
9. Omland T, Lie RT, Aakvaag A, Aarsland T, Dickstein K: Plasma endothelin determination as a prognostic indicator of 1-year mortality after acute myocardial infarction. Circulation 1994;89:1573-1579.
10. Lüscher TF, Barton M: Endothelins and endothelin receptor antagonists. Circulation 2000;102:2434-2440.
11. Agui T, Xin X, Cai Y, Sakai T, Matsumoto K: Stimulation of interleukin-6 production by endothelin in rat bone marrow-derived stromal cells. Blood 1994;84:2531-2538.
12. Hofman FM, Chen P, Jeyaseelan R, Incardona F, Fisher M, Zidovetzki R: Endothelin-1 induces production of the neutrophil chemotactic factor interleukin-8 by human brain-derived endothelial cells. Blood 1998;92:3064-3072.
13. Wigmore SJ, Fearon KCH, Maingay JP: Interleukin-8 can mediate acute-phase production by isolated human hepatocytes. Am J Physiol 1997;273:E720-E726.
14. Mackiewicz A, Shooltink H, Heinrich PC, Rose-John S: Complex of soluble human IL-6-receptor/IL-6 up regulates expression of acute phase proteins. J Immunol 1992;149:2021-2027.
15. Teder P, Noble PW: A cytokine reborn? Endothelin-1 in pulmonary inflammation and fibrosis. Am J Respir Cell Mol Biol 2000;23:7-10.
16. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, et al: A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988;332:411-415.
17. Finsnes F, Christensen G, Lyberg T, Sejersted OM, Skjonsberg OH: Increased synthesis and release of endothelin-1 during the initial phase of airway inflammation. Am J Respir Crit Care Med 1998;158;1600-1606.
18. Roland M, Bhowmik A, Sapsford RJ, Seemungal TA, Jeffries DJ, Warner TD, et al: Sputum and plasma endothelin-1 levels in exacerbations of chronic obstructive pulmonary disease. Thorax 2001;56:30-35.
19. Murch SH, Braegger CP, Sessa WC, Mac-Donald TT: High endothelin-1 immunoreactivity in Crohn's disease and ulcerative colitis. Lancet 1992;339:381-385.
20. Ihling C, Szombathy T, Bohrmann B, Brockhaus M, Schaefer HE, Loeffler BM: Coexpression of endothelin-converting enzyme and endothelin-1 in different stages of human atherosclerosis. Circulation 2001;104:864-869.
21. Verma S, Li SH, Badiwala MV, Weisel RD, Fedak PW, Li RK, et al: Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation 2002;105:1890-1896.
22. Katayama T, Yano K, Nakashima H, Takagi C, Honda Y, Suzuki S, Iwasaki Y: Clinical significance of acute-phase endothelin-1 in acute myocardial infarction patients treated with direct coronary angioplasty. Circ J 2005;69:654-658.
23. Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J, Sanchez-Pascuala R, Hernandez G, Diaz C, et al: Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest 1998;101:2711-2719.
24. Jialal I, Stein, D, Balis D, Grundy SM, Adams-Huet B, Devaraj S: Effect of hydroxymethyl glutaryl coenzyme A reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 2001;103:1933-1935.
25. Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS, et al: Measurement of Creactive protein for the targeting of statin theraphy in the primary prevention of acute coronary events. N Engl J Med 2001;344:1959-1965.